by myNEO Tx Admin | Nov 22, 2023 | Press release
CureVac has exercised its options on a selected set of potential cancer vaccine targets identified by myNEO Therapeutics under the existing partnership agreement Two option fee payments triggered to myNEO Therapeutics By applying its AI-based ImmunoEngine platform,...by myNEO Tx Admin | Nov 16, 2023 | Article, News
myNEO Therapeutics has been quite active in recent months, taking part in various conference presentations and participating in panel discussions. Additionally, we’re pleased to announce that our CEO, Cedric, received the Medical Genetics award at the Vexillum...The process starts with the collection of both patient blood and a tumor biopsy.
Whole-Genome Sequencing data from matched tumor and normal DNA is required for each patient.
Following alignment of these reads to the genome, somatic gene alterations in the tumor genome are detected using a collection of algorithms called 'neoX'.
Next, these somatic gene alterations are translated in-silico to obtain the tumor-specific peptides
In a last step, the peptides are prioritized using an immunogenicity predictor (neoIM) and two presentation predictors (neoMS and MHCrank).